Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 4 institutions in 2 countries.
Leonardo SorrentinoLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-3804-2946
Valentina SilvestriDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-0712-9379
Giuseppe OlivetoLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Mirko ScordioLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Federica FrascaLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Matteo FracellaLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Camilla BitossiLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Alessandra D'AuriaLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Letizia SantinelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy.ORCID 0000-0002-5621-058X
Lucia GabrieleDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-1483-866X
Alessandra PierangeliLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-0633-360X
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy.ORCID 0000-0002-1286-467X
Gabriella d'EttorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy.ORCID 0000-0002-3571-5677
Guido AntonelliLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Antonio CaruzImmunogenetic Unit, Department of Experimental Biology, University of Jaén, 23071 Jaén, Spain.ORCID 0000-0002-5788-7840
Laura OttiniDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Carolina ScagnolariLaboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-1044-1478
Sapienza University of Rome · ITPoliclinico Umberto I · ITIstituto Superiore di Sanità · ITUniversidad de Jaén · ES
Funding
Fondo di Beneficenza di Intesa Sanpaolo B/2020/0128Ministry of Health COVID-2020-12371817Sapienza Univeristy of Rome RM120172B29590C6Sapienza Univeristy of Rome RM12117A513C1DDD
6 · The paper itself
Abstract
Type III interferons (IFN-III), also known as IFN-Lambda, have a pivotal role during SARS-CoV-2 infection. IFN-Lambda response among individuals is heterogeneous and its association with COVID-19 symptoms severity needs to be further clarified. We analyzed the genotype frequencies of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.